| 1. |
- Andersson, Sören, 1957-, et al.
(författare)
-
CHIMERIC MOMP ANTIGEN
- 2015
-
Patent (populärvet., debatt m.m.)
|
|
| 2. |
- Eriksson, Leif A., 1964-, et al.
(författare)
-
Tetrazole derivatives as cytochrome p450 inhibitors
- 2019
-
Patent (populärvet., debatt m.m.)abstract
- According to the invention there is provided a compound of formula I, wherein R1 and R2 have meanings given in the description, which compounds are useful in the treatment of skin disorders and other diseases.
|
|
| 3. |
- Ragno, Rino, et al.
(författare)
-
Structure-based modeling and target-selectivity prediction
- 2014
-
Patent (populärvet., debatt m.m.)abstract
- The present invention provides, inter alia, methods, models, and systems for selecting an effector having specificity for a target molecule. The methods and systems of the present invention involve several steps, including compiling a database containing structural data for a library of molecules and a population of ligands and activity data, establishing structure-based equivalence of sequence elements in the library of molecules, determining likely spatial orientations of population ligands in library molecules, calculating interaction energies for each ligand-molecule pair, generating statistical models that are predictive of sequence elements likely to contribute to a differential effect of ligands on molecules, selecting an effector that is likely to have a desired specificity for the target molecule, experimentally determining activity data for effector-library molecule pairs, and at least once repeating the steps listed above wherein the effector is a member of the population of ligands.
|
|
| 4. |
- Andersson, Sören, 1957-, et al.
(författare)
-
Chimeric MOMP antigen
- 2014
-
Patent (populärvet., debatt m.m.)abstract
- The present invention regards polypeptides capable of eliciting an immunological response that is protective against Chlamydia trachomatis. The polypeptide comprises a first amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 1 and a second amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 2. Furthermore, production of these polypeptides and pharmaceutical compositions comprising them are also provided.
|
|
| 5. |
- Bidarian-Moniri, Armin
(författare)
-
Device for Equalization of the Pressure in the Middle Ear
- 2013
-
Patent (övrigt vetenskapligt/konstnärligt)abstract
- Device for the equalization of middle ear pressure for non-surgical ventilation of the middle ear for treatment of otitis media with effusion/serous otitis media in infants, children and adults.
|
|
| 6. |
|
|
| 7. |
- Almhöjd, Ulrica S., et al.
(författare)
-
Preparation for treatment of wounds and sores comprising hypochlorite and amino acids : WO 2014016157
- 2014
-
Patent (övrigt vetenskapligt/konstnärligt)abstract
- A kit of parts for use in prevention and/or treatment of sores, wounds, ulcers or the like, or a fistula or otitis. The kit of parts comprises a first aqueous component comprising one or more amino acids, and a second aqueous component comprising an active halogen compound, wherein the pH of the first component and/or the second component is about 9 to 11.5. There is also provided a treatment preparation prepared from the components and uses thereof in the prevention and/or treatment of sores, wounds, ulcers or the like, or a fistula or otitis.
|
|
| 8. |
- Hedhammar, My, et al.
(författare)
-
Spider silk fusion protein structures for binding to an organic target
- 2012
-
Patent (övrigt vetenskapligt/konstnärligt)abstract
- A protein structure capable of selective interaction with an organic target is provided. The protein structure is a polymer comprising as a repeating structural unit a recombinant fusion protein that is capable of selective interaction with the organic target. The fusion protein is comprising the moieties B, REP and CT, and optionally NT. B is a non-spidroin moiety of more than 30 amino acid residues, which provides the capacity of selective interaction with the organic target. REP is a moiety of from 70 to 300 amino acid residues and is derived from the repetitive fragment of a spider silk protein. CT is a moiety of from 70 to 120 amino acid residues and is derived from the C-terminal fragment of a spider silk protein. NT is an optional moiety of from 100 to 160 amino acid residues and is derived from the N-terminal fragment of a spider silk protein. The fusion protein and protein structure thereof is useful as an affinity medium and a cell scaffold material.
|
|
| 9. |
|
|
| 10. |
|
|
